AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. - Ishida M; Yamada T; Katayama Y; Kawachi H; Sawada R; Nakamura R; Hirai S; Matsui Y; Morimoto K; Onoi K; Nakamura-Sasada A; Horinaka M; et al. (NPJ precision oncology, 2026)